French Version of Fear-Avoidance Component Scale (FACS-FR)
Launched by UNIVERSITÉ DE SHERBROOKE · Jan 19, 2022
Trial Information
Current as of May 30, 2025
Completed
Keywords
ClinConnect Summary
The process is done in two steps to allow the achievement of our two study objectives (translation and validation), with two different cohorts of patients.
First, for the French translation of the FACS, a pre-test with a first cohort of 30 patients will be performed. These patients will have to fill in the French version of the paper questionnaire and answer a second one on their interpretation and understanding of the questions. Each question will be evaluated by the patient. A report will be made with the patients' answers to the questionnaire and reported to the translation committee, t...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • At least 18 years old
- • Current chronic pain complaint is not surgically treated (at least 6 weeks of pain)
- • Not being currently treated by a physiotherapist for pain complaint
- • French language is mother tongue
- Exclusion Criteria:
- • Pain from a non-musculoskeletal origin (e.g., tumour)
- • Neurological disease
- • Impaired cognition
About Université De Sherbrooke
The Université de Sherbrooke is a leading research institution in Canada, renowned for its commitment to advancing knowledge and innovation in various fields, including health sciences. With a focus on interdisciplinary collaboration, the university actively engages in clinical trials to explore new therapeutic interventions and improve patient care. Its research team comprises experienced professionals dedicated to ensuring the highest ethical standards and scientific rigor in clinical research. The Université de Sherbrooke strives to translate research findings into practical solutions that enhance health outcomes and contribute to the advancement of medical science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Sherbrooke, Quebec, Canada
Patients applied
Trial Officials
Guillaume Leonard, Pr
Study Director
Université de Sherbrooke
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials